Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jan 1;16(1):195-202.
doi: 10.1158/1078-0432.CCR-09-0948. Epub 2009 Dec 22.

A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer

Pamela L Paris  1 , Vivian Weinberg, Giancarlo Albo, Ritu Roy, Catherine Burke, Jeffry Simko, Peter Carroll, Colin Collins
Affiliations
Comparative Study

A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer

Pamela L Paris et al. Clin Cancer Res. .

Abstract

Purpose: The three main treatment options for primary prostate cancer are surgery, radiation, and active surveillance. Surgical and radiation intervention for prostate cancer can be associated with significant morbidity. Therefore, accurate stratification predictive of outcome for prostate cancer patients is essential for appropriate treatment decisions. Nomograms that use clinical and pathologic variables are often used for risk prediction. Favorable outcomes exist even among men classified by nomograms as being at high risk of recurrence.

Experimental design: Previously, we identified a set of DNA-based biomarkers termed Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) and have shown that they can predict risk of recurrence with 80% accuracy. Here, we examined the risk prediction ability of GEMCaP in a high-risk cohort and compared it to a Kattan nomogram.

Results: We determined that the GEMCaP genotype alone is comparable with the nomogram, and that for a subset of cases with negative lymph nodes improves upon it.

Conclusion: Thus, GEMCaP shows promise for predicting unfavorable outcomes for negative lymph node high-risk cases, where the nomogram falls short, and suggests that addition of GEMCaP to nomograms may be warranted.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: C. Collins: scientific advisory board, Combimatrix Molecular Diagnostics. P.L. Paris and C. Collins are inventors on a patent issued to UCSF. The other authors disclosed no potential conflicts of interest.

Figures

Fig. 1
Fig. 1
Agreement with GEMCaP and nomogram predictions. Horizontal dotted lines, 40% and 70% nomogram cut-points. ▲, favorable GEMCaP predictions; ●, unfavorable GEMCaP predictions. Data points within the ovals are where the nomogram and GEMCaP classification agree. Cases misclassified by both approaches are within the rectangle. Patients with intermediate nomogram scores (i.e., between the 40% and 70% cut-points) are those that might benefit the most from genomic analysis.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paris PL, Andaya A, Fridlyand J, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet. 2004;13:1303–13. - PubMed
    1. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562–8. - PubMed
    1. Paris PL, Weinberg V, Simko J, et al. Preliminary evaluation of prostate cancer metastatic risk biomarkers. Int J Biol Markers. 2005;20:141–5. - PubMed
    1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–71. - PubMed
    1. Paris PL, Albertson DG, Alers JC, et al. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am J Pathol. 2003;162:763–70. - PMC - PubMed

Publication types

Substances